NICE u-turn in favour of Amgen’s novel melanoma drug
The National Institute for Health and Care Excellence is now recommending NHS use of Amgen’s Imlygic to treat advanced melanoma that has spread and can’t be surgically removed.
Read More
Tag: talimogene laherparepvec
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
